Search results
Results from the WOW.Com Content Network
Patient is undergoing local hyperthermia treatment for head and neck cancer. Local hyperthermia heats a very small area and is typically used for cancers near or on the skin or near natural openings in the body (e.g., the mouth). [6] In some instances, the goal is to kill the tumor by heating it, without damaging anything else.
Cobimetinib, sold under the brand name Cotellic, is an anti-cancer medication used to treat melanoma and histiocytic neoplasms. [2] [8] Cobimetinib is a MEK inhibitor. [2] ...
Cancer treatments are a wide range of treatments available for the many different types of cancer, with each cancer type needing its own specific treatment. [1] Treatments can include surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy including small-molecule drugs or monoclonal antibodies, [2] and PARP inhibitors such as olaparib. [3]
Intense heating will cause denaturation and coagulation of cellular proteins, rapidly killing cells within a tumour. More prolonged moderate heating to temperatures just a few degrees above normal (39.5 °C) can cause more subtle changes. A mild heat treatment combined with other stresses can cause cell death by apoptosis.
c-Met inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor (HGF/SF). These inhibitors may have therapeutic application in the treatment of various types of cancers. [1] Many c-Met inhibitors are currently [when?] in clinical trials.
Interest in JQ1 as a cancer therapeutic stemmed from its ability to inhibit BRD4 and BRD3, both of which form fusion oncogenes that drive NUT midline carcinoma. [3] [4] Subsequent work demonstrated that a number of cancers including some forms of acute myelogenous leukemia (AML), multiple myeloma (MM), and acute lymphoblastic leukemia (ALL) were also highly sensitive to BET inhibitors.
Binimetinib is a selective inhibitor of MEK, a central kinase in the tumor-promoting MAPK pathway. [5] Inappropriate activation of the pathway has been shown to occur in many cancers. [ 5 ] In June 2018 it was approved by the FDA in combination with encorafenib for the treatment of patients with unresectable or metastatic BRAF V600E or V600K ...
Kanzius, self-taught, stated that he was motivated to research the subject of cancer treatment by his own experiences undergoing chemotherapy for treatment of non-Hodgkin's lymphoma. [ 4 ] [ 5 ] He died of B-cell leukemia with complications from pneumonia without seeing FDA approval and commercialization of his invention.